Illumina Paying up to $90M in Cash and Stock in Epicentre Acquisition
March 08, 2011
Illumina Paying up to $90M in Cash and Stock in Epicentre Acquisition
According to a filing with the Securities and Exchange Commission, Illumina acquired Epicentre for $60 million in cash as well as $15 million in stock that is "subject to forfeiture if certain non-revenue based milestones are not met." In addition, Illumina will pay up to $15 million in contingent considerations based on "certain revenue-based milestones" by Jan. 10, 2013.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Acquisition of Epicentre Gives Illumina Exclusive Access to Nextera Sample-Prep Method
January 18, 2011 / In Sequence - New Illumina Kits will Streamline Workflow, Lower DNA Input, Increase Multiplexing
July 3, 2012 / In Sequence - UW Team Adapts Transposase Library Prep for Ultra-Low-Input Whole-Genome Bisulfite Sequencing
April 10, 2012 / In Sequence - Illumina Sequencing Revenue Grows 70 Percent in Q4, Driven by HiSeq
February 15, 2011 / In Sequence - Illumina Buys Epicentre Biotechnologies, Launches MiSeq Platform
January 12, 2011 / GenomeWeb Daily News